Complexation study and anticellular activity enhancement by doxorubicin-cyclodextrin complexes on a multidrug-resistant adenocarcinoma cell line.
Ability of molecular complexes of [Doxorubicin (DX)-cyclodextrin (Cd)] to enhance the anticellular activity of antineoplastic drug Doxorubicin and to reverse its multidrug resistance has been investigated. A spectroscopic study of the alpha, beta, and gamma-[DX-Cds] complexes has been investigated in relation to their biological effects on a multidrug resistant (MDR) human rectal adenocarcinoma cell line (HRT-18). A ten fold enhancement of DX anticellular activity in presence of beta-cyclodextrin alone was detected.
D000970:Antineoplastic Agents / Q000737:chemistry* / Q000493:pharmacokinetics*; D002470:Cell Survival; D002942:Circular Dichroism; D003505:Cyclodextrins / Q000737:chemistry* / Q000493:pharmacokinetics*; D004317:Doxorubicin / Q000737:chemistry* / Q000493:pharmacokinetics*; D018432:Drug Resistance, Multiple; D006801:Humans; D008956:Models, Chemical; D013050:Spectrometry, Fluorescence; D013997:Time Factors; D014407:Tumor Cells, Cultured